DYN Q3 2016 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q3 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$241M-61.4% YoY

Gross Profit

-$419M-173.9% margin

Operating Income

-$117M-48.5% margin

Net Income

-$249M-103.3% margin

EPS (Diluted)

$-1.98

QoQ Revenue Growth

+45.2%

Cash Flow

Operating Cash Flow

$332M

Free Cash Flow

$297M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$13.0B

Total Liabilities

$10.8B

Stockholders' Equity

$2.2B

Cash & Equivalents

$1.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$241M	$625M	-61.4%
Gross Profit	-$419M	$4M	-10575.0%
Operating Income	-$117M	$107M	-209.3%
Net Income	-$249M	-$24M	-937.5%